Cost-Effectiveness Analysis of Biomarker-Guided Treatment for Metastatic Gastric Cancer in the Second-Line Setting.

Brianna N Lauren Sassan OstvarElisabeth SilverMyles IngramAaron OhLindsay KumbleMonika LaszkowskaJacqueline N ChuDawn L HershmanGulam ManjiAlfred I NeugutChin Hur

Published in: Journal of oncology (2020)

Biomarker-based treatments with targeted therapies/immunotherapies for second-line metastatic GC patients substantially improve unadjusted and quality-adjusted survival but are not cost-effective at current drug prices.

Keyphrases

end stage renal disease
squamous cell carcinoma
small cell lung cancer
newly diagnosed
ejection fraction
chronic kidney disease
peritoneal dialysis
prognostic factors
patient reported outcomes
high resolution
free survival
smoking cessation
simultaneous determination